Traders purchased shares of Allergan PLC (NYSE:AGN) on weakness during trading on Friday. $192.59 million flowed into the stock on the tick-up and $139.09 million flowed out of the stock on the tick-down, for a money net flow of $53.50 million into the stock. Of all equities tracked, Allergan PLC had the 20th highest net in-flow for the day. Allergan PLC traded down ($2.61) for the day and closed at $252.95

A number of brokerages recently commented on AGN. Nomura reissued a “buy” rating and issued a $330.00 price target (down previously from $350.00) on shares of Allergan PLC in a report on Tuesday, April 5th. Cowen and Company reissued a “buy” rating on shares of Allergan PLC in a report on Tuesday, April 5th. Leerink Swann reissued a “buy” rating and issued a $340.00 price target on shares of Allergan PLC in a report on Tuesday, April 5th. Credit Suisse Group AG started coverage on Allergan PLC in a report on Monday, July 25th. They set an “outperform” rating and a $327.00 target price on the stock. Finally, Vetr raised Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 target price on the stock in a report on Monday, July 25th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $308.74.

The firm has a 50 day moving average of $239.70 and a 200-day moving average of $253.84. The company has a market capitalization of $100.06 billion and a price-to-earnings ratio of 22.64.

Allergan PLC (NYSE:AGN) last announced its earnings results on Tuesday, May 10th. The company reported $3.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.01. The business had revenue of $3.80 billion for the quarter, compared to the consensus estimate of $3.97 billion. The firm’s revenue was up 48.1% compared to the same quarter last year. On average, equities research analysts anticipate that Allergan PLC will post $14.17 earnings per share for the current year.

In other news, Director Nesli Basgoz sold 459 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $225.10, for a total transaction of $103,320.90. Following the transaction, the director now directly owns 5,242 shares of the company’s stock, valued at $1,179,974.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Maria Teresa Hilado bought 661 shares of the stock in a transaction dated Thursday, June 2nd. The shares were acquired at an average cost of $241.57 per share, for a total transaction of $159,677.77. Following the completion of the acquisition, the chief financial officer now directly owns 11,957 shares of the company’s stock, valued at approximately $2,888,452.49. The disclosure for this purchase can be found here.

Several hedge funds and institutional investors have made changes to their positions in the company. Cowen Prime Services LLC boosted its position in shares of Allergan PLC by 264.7% in the fourth quarter. Cowen Prime Services LLC now owns 4,406 shares of the company’s stock valued at $1,377,000 after buying an additional 3,198 shares in the last quarter. Baldwin Investment Management LLC raised its stake in Allergan PLC by 20.9% in the fourth quarter. Baldwin Investment Management LLC now owns 5,367 shares of the company’s stock valued at $1,677,000 after buying an additional 926 shares in the last quarter. D L Carlson Investment Group Inc. raised its stake in Allergan PLC by 30.0% in the fourth quarter. D L Carlson Investment Group Inc. now owns 8,946 shares of the company’s stock valued at $2,796,000 after buying an additional 2,066 shares in the last quarter. Spectrum Management Group Inc. raised its stake in Allergan PLC by 1.7% in the fourth quarter. Spectrum Management Group Inc. now owns 4,874 shares of the company’s stock valued at $1,523,000 after buying an additional 80 shares in the last quarter. Finally, Liberty Mutual Group Asset Management Inc. raised its stake in Allergan PLC by 60.9% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 23,392 shares of the company’s stock valued at $7,310,000 after buying an additional 8,857 shares in the last quarter.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.